|
|
|
Prolactine
- Elisa
Immunoenzymetric assay for the in vitro quantitative measurement of human Prolactin (PRL) in serum and plasma. BL-25-E
for in vitro diagnostic use only
I.
CLINICAL BACKGROUND A.
Biological activities Prolactin
(PRL) is a polypeptide hormone (molecular weight 20,000 Da) secreted by the
pituitary gland, which plays a key role in the development of the mammary
gland, the production and secretion of milk and the control of male and female
gonadal functions. Prolactin
secretion is under hypothalamic control exerted directly by dopamine, several
prolactin releasing factors (PRF) and perhaps VIP (vasoactive intestinal
polypeptide) or a closely related peptide.
TRH also acts directly at the pituitary level to stimulate prolactin
release but its physiological role in the control of prolactin secretion has
not been established yet. Several
neuroendocrine factors, involving serotoninergic or noradrenergic pathways are
also involved in the control of prolactin secretion.
The plasma concentration of prolactin increases in various
physiological situations such as stress, pregnancy and lactation.
Physiological levels fluctuate according to a nycthemeral rhythm, a
significant rise being observed at night.
Drugs with anti‑dopamine activity (psychotropic agents) and
ovulatory suppressants, increase prolactin secretion. B.
Clinical application ·
Prolactinoma : Circulating
prolactin levels are elevated in patients with a prolactin secreting pituitary
adenoma. Amenorrhea and impotence
are characteristic clinical symptoms in such cases. ·
Other pituitary diseases :
Increased prolactin levels are also observed in 5% to 20% of patients with
acromegaly and when pituitary control by the hypothalamus is suppressed
(pituitary stalk section). Decreased
PRL levels may be observed in cases of complete destruction of the pituitary
as in Sheehan's syndrome. ·
Galactorrhea and amenorrhea :
The measurement of the prolactin levels in serum is a useful test in the
differential diagnosis of galactorrhea and amenorrhea.
II.
PRINCIPLES OF
THE METHOD The
Bio-Line PRL-ELISA is a solid phase Enzyme Amplified Sensitivity Immunoassay
performed on microtiterplate. The
assay uses monoclonal antibodies (MAbs) directed against distinct epitopes of
Prolactin. Calibrators and
samples react with the capture monoclonal antibody (MAb 1) coated on microtiter
well and with a monoclonal antibody (MAb 2) labelled with horseradish peroxidase
(HRP). After an incubation period
allowing the formation of a sandwich: coated MAb 1 – human Prolactin – MAb 2
– HRP, the microtiterplate is washed to remove unbound enzyme labelled
antibody. Bound
enzyme-labelled antibody is measured through a chromogenic reaction. Chromogenic solution (TMB) is added and incubated.
The reaction is stopped with the addition of Stop Solution and the
microtiterplate is then read at the appropriate wavelength.
The amount of substrate turnover is determined colourimetrically by
measuring the absorbance, which is proportional to the Prolactin concentration.
A
calibration curve is plotted and PRL concentration in samples is determined by
interpolation from the calibration curve. The
use of the ELISA reader (linearity up to 3 OD units) and a sophisticated data
reduction method (polychromatic data reduction) result in a high sensitivity in
the low range and in an extended calibration range. III. REAGENTS PROVIDED
Note:
1.
Use the zero calibrator for sample dilutions. 2.
1 ng of the calibrator
preparation is equivalent to 30 ± 2 μIU MRC 3rd IRP 84/500. IV.
SUPPLIES NOT PROVIDED The following material is
required but not provided in the kit: 1.
High quality distilled water 2.
Pipettes for delivery of: 25 µl, 50
μl, 100 µl, 200 μl, 500 µl and 2 ml (the use of accurate pipettes
with disposable plastic tips is recommended) 3.
Vortex mixer 4.
Magnetic stirrer 5.
Horizontal microtiterplate shaker
capable of 700 rpm ± 100 rpm 6.
Washer for Microtiterplates 7.
Microtiterplate reader capable of
reading at 450 nm, 490 nm and 650 nm (in case of polychromatic reading) or
capable of reading at 450 nm and 650 nm (monochromatic reading) 8.
Optional equipment: The ELISA-AID™
necessary to read the plate according to polychromatic reading (see paragraph
XI.A.) can be purchased from Robert Maciels Associates, Inc. Mass. 0.2174 USA. V. REAGENT PREPARATION a.
Calibrators
: Reconstitute the zero calibrator with 2.0 ml distilled water and other
calibrators with 0.5 ml distilled water. b.
Controls
: Reconstitute the controls with 0.5 ml distilled water. c.
Working
Wash solution : Prepare an adequate volume of
Working Wash solution by adding 199 volumes of distilled water to 1 volume of
Wash Solution (200x). Use a magnetic stirrer to homogenize. Discard unused
Working Wash solution at the end of the day.
d.
Revelation
Solution: pipette 0.2 ml of the chromogen TMB
into one of the vials of substrate buffer (H2O2 in
acetate/citrate buffer). Extemporaneous
preparation is recommended. VI.
STORAGE AND
EXPIRATION DATING
OF REAGENTS §
Before opening or reconstitution, all
kits components are stable until the expiry date, indicated on the vial label,
if kept at 2 to 8°C. §
Unused strips must be stored, at 2-8°C,
in a sealed bag containing a desiccant until expiration date. §
After reconstitution, calibrators and
controls are stable for 1 week at 2 to 8°C. For longer storage periods,
aliquots should be made and kept at ‑20°C for maximum 3 months. Avoid successive freeze thaw cycles. §
The concentrated Wash Solution is
stable at room temperature until expiration date. §
Freshly prepared Working Wash solution
should be used on the same day. §
After its first use, the conjugate is
stable until expiry date, if kept in the original well-closed vial at 2 to 8°C. §
The freshly prepared revelation
solution is stable, before use, for maximum 15 minutes at room temperature and
must be discarded afterwards. §
Alterations in physical appearance of
kit reagents may indicate instability or deterioration. VII. SPECIMEN COLLECTION AND PREPARATION §
Serum and plasma must be kept at 2 - 8°C. §
If the test is not run within 24 hours,
storage in aliquots at -20°C is recommended.
Avoid subsequent freeze thaw cycles. §
Prior to use, all samples should be at
room temperature. It is recommended
to vortex the samples before use. §
Serum or plasma (EDTA and heparin
plasma) provides similar results. Y(serum) =
0.88 x (EDTA plasma) + 0.7
r=0.96 n=69 Y(serum) = 1.01 x (Heparin
plasma) – 9.0 r=0.97
n=69 §
Do not use haemolysed samples. VIII. PROCEDURE A.
Handling notes
Do not use the kit or components beyond expiry date. Do not mix materials from
different kit lots. Bring all the reagents to room
temperature prior to use.
Thoroughly mix all reagents and samples by gentle agitation or swirling.
Perform calibrators, controls and samples in duplicate. Vertical alignment is recommended.
Use a clean plastic container to prepare the Wash Solution.
In order to avoid cross-contamination, use a clean disposable pipette tip
for the addition of each reagent and sample.
For the dispensing of the Revelation Solution and the Stop Solution avoid
pipettes with metal parts.
High precision pipettes or automated pipetting equipment will improve the
precision.
Respect the incubation times.
To avoid drift, the time between pipetting of the first calibrator and
the last sample must be limited to the time mentioned in section XIII paragraph
E (Time delay).
Prepare a calibration
curve for each run, do not use data from previous runs. Dispense the Revelation Solution within 15 minutes
following the washing of the microtiterplate.
During incubation with Revelation Solution, avoid
direct sunlight on the microtiterplate. B.
Procedure 1. Select the required number of strips for the run. The unused strips should be resealed in the bag with a desiccant and stored at 2-8°C. 2. Secure the strips into the holding frame. 3. Pipette 25 µl of each Calibrator, Control and Sample into the appropriate wells. 4. Pipette 100 µl of anti-PRL-HRP conjugate into all the wells. 5. Incubate for 30 minutes at room temperature on a horizontal shaker set at 700 rpm ± 100 rpm. 6. Aspirate the liquid from each well. 7. Wash the plate 3 times by: § Dispensing 0.4 ml of Wash Solution into each well § Aspirating the content of each well 8. Pipette 200 µl of the freshly prepared revelation solution into each well within 15 minutes following the washing step. 9. Incubate the microtiterplate for 15 minutes at room temperature on a horizontal shaker set at 700 rpm ± 100 rpm, avoid direct sunlight. 10. Pipette 50 µl of Stop solution into each well. 11. Read the absorbencies at 450 nm and 490 nm (reference filter 630 nm or 650 nm) within 1 hour and calculate the results as described in section XI. IX.
CALCULATION OF
RESULTS A.
Polychromatic Reading: 1.
In this case, the ELISA-AID™ software
will do the data processing. 2.
The plate is first read at 450 nm
against a reference filter set at 650 nm (or 630 nm). 3.
A second reading is performed at 490 nm
against the same reference filter. 4.
The ELISA-AID™ Software will drive
the reader automatically and will integrate both readings into a polychromatic
model. This technique can generate
OD’s up to 10. 5.
The principle of polychromatic data
processing is as follows: §
Xi = OD at 450 nm §
Yi = OD at 490 nm §
Using a standard unweighted linear
regression, the parameters A & B are calculated : Y = A*X – B §
If Xi < 3 OD units, then X
calculated = Xi §
If Xi > 3 OD units, then X
calculated = (Yi-B)/A §
A 4 parameter logistic curve fitting is
used to build up the calibration curve. §
The prolactin concentration in samples
is determined by interpolation on the calibration curve. B.
Bichromatic Reading 1.
Read the plate at 450 nm against a
reference filter set at 650 nm (or 630 nm). 2.
Calculate the mean of duplicate
determinations. 3.
On semi-logarithmic or linear graph
paper plot the OD values (ordinate) for each calibrator against the
corresponding concentration of PRL (abscissa) and draw a calibration curve
through the calibrator points by connecting the plotted points with straight
lines. 4.
Read the concentration for each control
and sample by interpolation on the calibration curve. 5.
Computer assisted data reduction will
simplify these calculations. If
automatic result processing is used, a 4 parameter logistic function curve
fitting is recommended.
X.
TYPICAL DATA The
following data are for illustration only and should never be used instead of the
real time calibration curve.
XI. PERFORMANCE AND LIMITATIONS A.
Detection Limit Twenty
zero calibrators were assayed along with a set of other calibrators. The
detection limit, defined as the apparent concentration two standard deviations
above the average OD at zero binding, was 11 μIU/ml. B.
Specificity The
Cross-reactivity of LH, FSH, hCG, hPL, TSH and hGH was determined by addition of
each analyte to serum samples containing respectively 116 µIU/ml and 2539 µIU/ml
of PRL. The apparent PRL
concentration was measured. As
shown below, the cross-reactions with LH, FSH, hCG, hPL, TSH and hGH are
insignificant
C.
Precision
SD
: Standard Deviation; CV: Coefficient of variation D.
Accuracy
RECOVERY
TEST
Samples
were diluted with zero calibrator. E.
Time delay between last calibrator and sample dispensing As shown hereafter, assay
results remain accurate even when a sample is dispensed 40 minutes after the
calibrators have been added to the coated wells.
F. Hook effect A
sample spiked with PRL up to 420000 μIU/ml gives higher OD’s than the
last calibrator point. XII.
INTERNAL QUALITY
CONTROL §
If the results obtained for Control 1
and/or Control 2 are not within the range specified on the vial label, the
results cannot be used unless a satisfactory explanation for the discrepancy has
been given. §
If desirable, each laboratory can make
its own pools of control samples, which should be kept frozen in aliquots. §
Acceptance criteria for the difference
between the duplo results of the samples should rely on Good Laboratory
Practises §
It is recommended that Controls be
routinely assayed as unknown samples to measure assay variability.
The performance of the assay should be monitored with quality control
charts of the controls. §
It is good practise to check visually
the curve fit selected by the computer. XIII.
REFERENCE INTERVALS These
values are given only for guidance; each laboratory should establish its own
normal range of values.
XIV. PRECAUTIONS AND WARNINGS Safety For
in vitro diagnostic use only. The
human blood components included in this kit have been tested by European
approved and/or FDA approved methods and found negative for HBsAg, anti-HCV,
anti-HIV-1 and 2. No known method
can offer complete assurance that human blood derivatives will not transmit
hepatitis, AIDS or other infections. Therefore,
handling of reagents, serum or plasma specimens should be in accordance with
local safety procedures. All
animal products and derivatives have been collected from healthy animals. Bovine
components originate from countries where BSE has not been reported.
Nevertheless, components containing animal substances should be treated as
potentially infectious. Avoid
any skin contact with all reagents, Stop
Solution contains H2SO4, the chromogen contains TMB in
Dimethylformamide, Substrate buffer contains H2O2.
In case of contact, wash thoroughly with water. Do
not smoke, drink, eat or apply cosmetics in the working area.
Do not pipette by mouth. Use
protective clothing and disposable gloves.
XV.
BIBLIOGRAPHY 1.
Archer D.F. ( 1977). Current
concepts of prolactin physiology in normal and abnormal conditions. Fertil Steril 28:125. 2.
Laufer N., Botero‑Ruiz W.,
De Chemey A.H., et al. (1984). Gonadotropin
and prolactin levels in follicular fluid of human ova successfully fertilized in
vitro. J. Clin. Endocrinal. Metab.
58:430. 3.
Leong D.A., Frawley L.S., Neil J.D.
( 1983). Neuroendocrine
control of prolactin secretion. An. Rev. of Physiol. 45:109. 4.
Seppala M. (1978). Prolactin
and female reproduction. An. Clin. Res. 10:164. 5.
Taylor T.J., Trouson A, Besanko
M., Burger H.G., Stockdale J. ( 1986). Plasma
progesterone and prolactin changes in superovulated women before, during and
immediatemy after laparoscopy for in vitro fertilisation and their relation to
pregnancy Fertil. Steril 45:680. 6.
Tyson J.E. ( 1980) Changing
role of placental lactogen and prolactin in human gestation. Clin.
Obstet.Gynecol 23:737. 7.
Kamel M.A et al ( 1994) Comparison
between prolactin, gonadotropins and steroid hormones in serum and follicular
fluid after stimulation with gonadotrophin‑releasing hormone agonist and
human menopausal gonadotrophin for an in-vitro fertilization program. Hum.
Reprod. 9(10):1803‑6. 8.
Patel D.D. et al (1994). Plasma
prolactin in patients with colorectal cancer. Value in follow‑up and as a
prognosticator Cancer
73(3):570-74. 9.
Hattori et al ( 1994). Effects
of anti‑prolactin autoantibodies on serum prolactin mesurements. Eur. J. Endocrinol.
130(5):434‑7. XVI.
SUMMARY OF THE PROTOCOL
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|